Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104766 | 0.82 | ATAD2 (0.45) | ATAD2CYP3A4TSHRMAPK1BRD4 | |
| SCHEMBL13481160 | 0.78 | ATAD2 (0.39) | ATAD2BRD4BAZ2BBAZ2ACREBBP | |
| SCHEMBL2116180 | 0.77 | BRD4 (0.36) | ATAD2BRD4BAZ2BBAZ2ACREBBP | |
| SCHEMBL12261136 | 0.76 | ATAD2 (0.35) | ATAD2CYP3A4BAZ2BBAZ2ACREBBP | |
| SCHEMBL12172358 | 0.73 | MAP2K2 (0.39) | ATAD2BRD4BAZ2BBAZ2ACREBBP | |
| SCHEMBL6239638 | 0.73 | BRD4 (0.36) | ATAD2BRD4BAZ2BBAZ2ACREBBP | |
| SCHEMBL25254931 | 0.71 | BRD4 (0.49) | BRD4CREBBP | |
| SCHEMBL24196406 | 0.71 | BRD4 (0.42) | ATAD2BRD4CREBBPAURKATTK | |
| SCHEMBL19701935 | 0.70 | ALDH1A1 (0.35) | ATAD2TSHRBRD4BAZ2BBAZ2A | |
| SCHEMBL29911866 | 0.70 | BAZ2B (0.37) | ATAD2BRD4BAZ2BBAZ2ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116406272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-114315834-A | Imidazolidinone derivatives and their use in medicaments | 成都百裕制药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114195805-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113956272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)有限公司 | 2022-01-21 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
| EP-2855483-B1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-9365576-B2 | Pyrrolopyrrolidinone compounds | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9365576-B2 | Pyrrolopyrrolidinone compounds | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| EP-2855483-A1 | PYRROLOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013175417-A1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013175417-A1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | ATAD2 4426/4885CYP3A4 35/4885TSHR 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.